drugset / Trial / NCT01774578
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.
Timeline
- Start
- 2013-02
- Primary completion
- 2016-05-18
- Completion
- 2016-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Tergenpumatucel-L | Vaccine | 3e+08 cells | Intramuscular |
| Background | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |